What COVID-19 Means for Surprise Billing

The last thing anyone impacted by COVID-19 needs is an unexpected medical bill. Yet health insurance industry experts say that likely will happen to some patients.

ICER Misses the Numbers That Matter

The Institute for Clinical and Economic Review wants to assess the cost-effectiveness of breakthrough drugs for cystic fibrosis. But their analysis overlooks key points. View the Graphic

Uniting in the Fight against Brain Illness

The number of people with Parkinson’s disease doubled from 1990 to 2015 – and is expected to double again over the next 20 years. The disease’s growing prevalence underscores why increased awareness and research for brain illness remain critical.

Comments on ICER’s Draft Evidence Report: Modulator Treatments for Cystic Fibrosis

Cystic fibrosis is a devastating disease that severely restricts patients’ quality of life and is associated with a shorter lifespan. The economic costs for managing cystic fibrosis are high. According to the American Thoracic Society, the average cost of care for cystic fibrosis was $48,000 in 2006. A good deal of these costs are costs […]